Published in Semin Oncol on December 01, 2009
The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol (2011) 2.33
Body mass index and risk of lung cancer among never, former, and current smokers. J Natl Cancer Inst (2012) 2.13
Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer. J Thorac Oncol (2012) 1.60
Reproductive and hormonal factors and lung cancer risk in the NIH-AARP Diet and Health Study cohort. Cancer Epidemiol Biomarkers Prev (2011) 1.20
Enhanced expression of G-protein coupled estrogen receptor (GPER/GPR30) in lung cancer. BMC Cancer (2012) 1.09
Lung cancer chemoprevention: current status and future prospects. Nat Rev Clin Oncol (2013) 1.09
Sex differences and sex steroids in lung health and disease. Endocr Rev (2012) 1.07
A review of the carcinogenic potential of bisphenol A. Reprod Toxicol (2015) 0.92
Aspirin and NSAID use and lung cancer risk: a pooled analysis in the International Lung Cancer Consortium (ILCCO). Cancer Causes Control (2011) 0.89
International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators. Pharmacol Rev (2015) 0.87
Invited commentary: the etiology of lung cancer in men compared with women. Am J Epidemiol (2013) 0.85
Estradiol activates epithelial sodium channels in rat alveolar cells through the G protein-coupled estrogen receptor. Am J Physiol Lung Cell Mol Physiol (2013) 0.85
Reproductive factors and risk of lung cancer in female textile workers in Shanghai, China. Cancer Causes Control (2013) 0.83
Concentration of endogenous estrogens and estrogen metabolites in the NCI-60 human tumor cell lines. Genome Med (2012) 0.83
Targeting the intracellular MUC1 C-terminal domain inhibits proliferation and estrogen receptor transcriptional activity in lung adenocarcinoma cells. Mol Cancer Ther (2011) 0.82
Body mass index and risk of lung cancer: Systematic review and dose-response meta-analysis. Sci Rep (2015) 0.82
Estrogen signaling in lung cancer: an opportunity for novel therapy. Cancers (Basel) (2012) 0.81
Ligand-dependent differences in estrogen receptor beta-interacting proteins identified in lung adenocarcinoma cells corresponds to estrogenic responses. Proteome Sci (2011) 0.80
Unopposed estrogen and estrogen plus progestin menopausal hormone therapy and lung cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Causes Control (2012) 0.80
Stimulatory actions of IGF-I are mediated by IGF-IR cross-talk with GPER and DDR1 in mesothelioma and lung cancer cells. Oncotarget (2016) 0.78
Potential therapeutic benefit of combining gefitinib and tamoxifen for treating advanced lung adenocarcinoma. Biomed Res Int (2015) 0.78
Overexpression of estrogen receptor beta is a prognostic marker in non-small cell lung cancer: a meta-analysis. Int J Clin Exp Med (2015) 0.77
Body mass index change in adulthood and lung and upper aerodigestive tract cancers. Int J Cancer (2012) 0.77
ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations. Sci Rep (2015) 0.77
Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER. Front Endocrinol (Lausanne) (2013) 0.76
Obesity in relation to lung cancer incidence in African American women. Cancer Causes Control (2013) 0.76
Raloxifene and antiestrogenic gonadorelin inhibits intestinal tumorigenesis by modulating immune cells and decreasing stem-like cells. Cancer Prev Res (Phila) (2014) 0.76
Human rhabdomyosarcoma cells express functional pituitary and gonadal sex hormone receptors: Therapeutic implications. Int J Oncol (2016) 0.76
Clinical features and prognosis-associated factors of non-small cell lung cancer exhibiting symptoms of bone metastasis at the time of diagnosis. Oncol Lett (2015) 0.76
Testicular orphan nuclear receptor 4-associated protein 16 promotes non-small cell lung carcinoma by activating estrogen receptor β and blocking testicular orphan nuclear receptor 2. Oncol Rep (2012) 0.75
Survival in women with NSCLC: the role of reproductive history and hormone use. J Thorac Oncol (2014) 0.75
The regulation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumor promotion by estradiol in female A/J mice. PLoS One (2014) 0.75
Correlation between epidermal growth factor receptor mutations and the expression of estrogen receptor-β in advanced non-small cell lung cancer. Oncol Lett (2017) 0.75
Association between the COMT 158 G/A polymorphism and lung cancer risk: a meta-analysis. Int J Clin Exp Med (2015) 0.75
[Primary lung adenocarcinoma: experience of a Tunisian hospital]. Pan Afr Med J (2015) 0.75
Women Epidemiology Lung Cancer (WELCA) study: reproductive, hormonal, occupational risk factors and biobank. BMC Public Health (2017) 0.75
GPER modulators: Opportunity Nox on the heels of a class Akt. J Steroid Biochem Mol Biol (2017) 0.75
Sex-specific incidence of EGFR mutation and its association with age and obesity in lung adenocarcinomas: a retrospective analysis. J Cancer Res Clin Oncol (2017) 0.75
Menstrual and reproductive factors and lung cancer risk: A pooled analysis from the International Lung Cancer consortium (ILCCO). Int J Cancer (2017) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst (1998) 22.10
Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A (1996) 10.94
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med (2004) 10.41
The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell (1998) 9.96
Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (1997) 9.09
Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science (1995) 6.37
Molecular determinants for the tissue specificity of SERMs. Science (2002) 6.20
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22
Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology (2003) 4.96
ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett (1996) 4.77
The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer (1980) 3.34
Lung cancer incidence in never smokers. J Clin Oncol (2007) 3.20
Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol (2005) 2.88
Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res (2002) 2.52
NRF-1, an activator involved in nuclear-mitochondrial interactions, utilizes a new DNA-binding domain conserved in a family of developmental regulators. Genes Dev (1993) 2.34
Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst (2000) 2.33
Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res (2005) 2.28
Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res (2000) 2.16
Mitochondrial localization of estrogen receptor beta. Proc Natl Acad Sci U S A (2004) 2.15
Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids (2007) 1.80
Functional estrogen receptors in the mitochondria of breast cancer cells. Mol Biol Cell (2006) 1.72
The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J Endocrinol (2009) 1.71
Mitochondrial localization of ERalpha and ERbeta in human MCF7 cells. Am J Physiol Endocrinol Metab (2004) 1.66
Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database. Chest (2005) 1.65
Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J Clin Oncol (2007) 1.62
Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res (2005) 1.59
Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids (2005) 1.57
Aromatase inhibitors in human lung cancer therapy. Cancer Res (2005) 1.55
The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg (2005) 1.55
Aromatase expression predicts survival in women with early-stage non small cell lung cancer. Cancer Res (2007) 1.54
Engineering of a mouse for the in vivo profiling of estrogen receptor activity. Mol Endocrinol (2001) 1.53
Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res (1987) 1.53
Progesterone receptor in non-small cell lung cancer--a potent prognostic factor and possible target for endocrine therapy. Cancer Res (2005) 1.51
Regulation of postnatal lung development and homeostasis by estrogen receptor beta. Mol Cell Biol (2003) 1.44
Estradiol stimulates transcription of nuclear respiratory factor-1 and increases mitochondrial biogenesis. Mol Endocrinol (2007) 1.41
Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res (2005) 1.40
Targeting aromatase and estrogen signaling in human non-small cell lung cancer. Ann N Y Acad Sci (2009) 1.39
Estrogenic control of mitochondrial function and biogenesis. J Cell Biochem (2008) 1.37
Lung dysfunction causes systemic hypoxia in estrogen receptor beta knockout (ERbeta-/-) mice. Proc Natl Acad Sci U S A (2006) 1.37
Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma. Endocr Relat Cancer (2008) 1.34
Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res (2008) 1.33
Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer (2007) 1.32
Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res (1999) 1.26
Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. Cancer Treat Rev (2007) 1.26
Functional differences between the amino-terminal domains of estrogen receptors alpha and beta. Mol Pharmacol (2000) 1.24
Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells. J Steroid Biochem Mol Biol (2009) 1.22
Binding of MCF-7 cell mitochondrial proteins and recombinant human estrogen receptors alpha and beta to human mitochondrial DNA estrogen response elements. J Cell Biochem (2004) 1.19
Combined overexpression of EGFR and estrogen receptor alpha correlates with a poor outcome in lung cancer. Anticancer Res (2005) 1.16
Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res (1994) 1.16
Estrogen receptor beta functions through nongenomic mechanisms in lung cancer cells. Mol Endocrinol (2008) 1.14
Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer (2008) 1.11
Estrogen actions on mitochondria--physiological and pathological implications. Mol Cell Endocrinol (2008) 1.11
Hormone replacement therapy as a risk factor for non-small cell lung cancer: results of a case-control study. Oncology (2008) 1.11
Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer (2008) 1.10
Estradiol and nicotine exposure enhances A549 bronchioloalveolar carcinoma xenograft growth in mice through the stimulation of angiogenesis. Int J Oncol (2006) 1.05
Estrogen receptor beta as a mitochondrial vulnerability factor. J Biol Chem (2009) 1.02
Lung cancer pathology in smokers, ex-smokers and never smokers. Cancer Lett (1995) 0.97
Subcellular distribution of native estrogen receptor alpha and beta subtypes in cultured human lens epithelial cells. Exp Eye Res (2004) 0.97
Widespread tissue distribution of steroid sulfatase, 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD), 17 beta-HSD 5 alpha-reductase and aromatase activities in the rhesus monkey. Mol Cell Endocrinol (1994) 0.94
Tissue- and time-dependent estrogen receptor activation in estrogen reporter mice. J Mol Endocrinol (2004) 0.90
Blockade of estrogen receptor signaling inhibits growth and migration of medulloblastoma. Endocrinology (2008) 0.90
Relative expression of aromatase cytochrome P450 in human fetal tissues as determined by competitive polymerase chain reaction amplification. J Clin Endocrinol Metab (1992) 0.89
Expression and subcellular distribution of native estrogen receptor beta in murine C2C12 cells and skeletal muscle tissue. Steroids (2009) 0.87
Non-genomic effects of 17beta-estradiol in activation of the ERK1/ERK2 pathway induces cell proliferation through upregulation of cyclin D1 expression in bovine artery endothelial cells. Gynecol Endocrinol (2007) 0.87
Estrogen replacement in female lung cancer during gefitinib therapy. Jpn J Clin Oncol (2009) 0.85
Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer. J Thorac Oncol (2012) 1.60
HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res (2009) 1.57
Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol (2004) 1.35
The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis. J Histochem Cytochem (2009) 1.30
Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma. Clin Cancer Res (2009) 1.26
Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells. J Steroid Biochem Mol Biol (2009) 1.22
Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin Cancer Res (2011) 1.15
Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther (2002) 1.14
Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells. Int J Cancer (2010) 1.13
CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int J Cancer (2006) 1.12
Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer (2008) 1.11
The antitumor efficacy of calcitriol: preclinical studies. Anticancer Res (2006) 1.05
Hepatocyte growth factor and other fibroblast secretions modulate the phenotype of human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol (2007) 1.02
Nuclear vitamin D receptor expression is associated with improved survival in non-small cell lung cancer. J Steroid Biochem Mol Biol (2010) 0.99
Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non small-cell lung cancer. Mol Pharmacol (2007) 0.97
1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model. Mol Cancer Ther (2008) 0.96
Vitamin D-related therapies in prostate cancer. Cancer Metastasis Rev (2002) 0.95
C16 ceramide accumulates following androgen ablation in LNCaP prostate cancer cells. Prostate (2003) 0.93
CYP24 inhibition preserves 1α,25-dihydroxyvitamin D(3) anti-proliferative signaling in lung cancer cells. Mol Cell Endocrinol (2012) 0.91
Inhibition of the splicing of glucose-6-phosphate dehydrogenase precursor mRNA by polyunsaturated fatty acids. J Biol Chem (2002) 0.91
Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice. Cancer Chemother Pharmacol (2010) 0.89
Mutation and polymorphism in the EGFR-TK domain associated with lung cancer. J Thorac Oncol (2006) 0.89
Nutritional regulation of mRNA processing. J Nutr (2004) 0.89
24-Hydroxylase in cancer: impact on vitamin D-based anticancer therapeutics. J Steroid Biochem Mol Biol (2012) 0.85
1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) Signaling Capacity and the Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer (NSCLC): Implications for Use of 1,25(OH)2D3 in NSCLC Treatment. Cancers (Basel) (2013) 0.83
Vitamin D receptor: a potential target for intervention. Urology (2002) 0.83
Elevated hepatocyte growth factor level correlates with poor outcome in early-stage and late-stage adenocarcinoma of the lung. Chest (2004) 0.81
Breast cancer-derived M543V mutation in helix 12 of estrogen receptor alpha inverts response to estrogen and SERMs. Breast Cancer Res Treat (2009) 0.79
A local effect of CYP24 inhibition on lung tumor xenograft exposure to 1,25-dihydroxyvitamin D(3) is revealed using a novel LC-MS/MS assay. Steroids (2012) 0.79
Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Melanoma Res (2014) 0.78
Inhibition of estrogen receptor alpha-mediated transcription by antiestrogenic 1,1-dichloro-2,2,3-triarylcyclopropanes. Mol Pharmacol (2004) 0.77
Genetic variation in ESR2 and estrogen receptor-beta expression in lung tumors. Cancer Epidemiol (2013) 0.75
Characterization of the metabolism of benzaldehyde dimethane sulfonate (NSC 281612, DMS612). Cancer Chemother Pharmacol (2015) 0.75